XML 30 R24.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

License, Collaboration and Service Agreements (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Schedule of remaining potential milestone payments | Remaining potential payments are milestone and royalty based, and are as follows (in millions):
Event |  | Milestone payments (up to)
GSK’s submission of a new drug application with the FDA for tebipenem HBr |  | $25.0
Total potential commercial milestone payments based on first sale (US/EU) |  | $150.0
Total potential sales milestone payments |  | $225.0
Royalties |  | Low-single digit to low-double digit (if sales exceed $1.0 billion) tiered royalties on net product sales

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the entity's accounting policy for the recognition of revenue under the milestone method. Includes: (1) a description of the overall arrangement; (2) a description of each milestone and related contingent consideration; (3) a determination of whether each milestone is considered substantive; (4) the factors that the entity considered in determining whether the milestone or milestones are substantive; and (5) the amount of consideration recognized during the period for the milestone or milestones. + References No definition available. + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration